MG

Martin Glen

Investment Director at Parkwalk Advisors; Director at Cytora, PsyOmics, Gripable and Wayland Additive

Greater London, England

Invests in

Locations:

  • Min Investment:

    $1,300,000.00
  • Max Investment:

    $2,000,000.00
  • Target Investment:

    $1,600,000.00

Skills

Investment Governance
Investment Management
Hedge Funds
Valuation
Alternative Investments
Bloomberg
Financial Modeling
Asset Management
Equity Research
Capital Markets
Investment Banking
Emerging Markets
Business Analysis
Equities
Trading
IPO
Portfolio Management
Investments

Education

  • B.A. (Hons)

    St. Edmund Hall, Oxford University

    (1983 - 1987)

  • Tonbridge School

    (1977 - 1983)

Work Experience

  • Investment Director

    2022

    Gripable is developing a digital platform for rehabilitation, gamifying exercises with novel devices, gathering data for monitoring and optimising treatment, helping patients, service providers and healthcare payors by increasing efficiency and generating superior outcomes.

  • Investment Director

    2016

    Parkwalk Advisors (www.parkwalkadvisors.com) is a leading technology growth EIS investment manager. We focus on UK university spin-out companies, largely in knowledge intensive, 'hard' science. Meet and engage with some amazing people and their brilliant ideas that will hopefully continue to support UK plc and change the world through the next few decades.

  • Non Executive Director

    2021

  • Director

    2017

2017

  • Director

    2017

Charco Neurotech

2021 - 2024

  • Non Executive Director

    2021 - 2024

2014 - 2015

  • Partner

    2014 - 2015

    European equity portfolio management, especially Industrials, and the IPO market in a special situations fund

Meditor

2005 - 2014

  • Analyst/Portfolio Manager

    2005 - 2014

    Nine years managing the deal desk at Meditor. Analysing IPOs and follow-on offerings across all sectors and all geographies from a fundamental perspective. Dealing in chosen investments and forming excellent relationships with syndicate/ECM departments at counterparties. Involved in the process from pre-IPO / pilot fishing all the way to aftermarket trading.

Jefferies Europe

2003 - 2005

  • Analyst/sales

    2003 - 2005

    An attempt at sales, firstly specialist sales for UK & European pharmaceutical analysts and then a more generalised salesman for the European small and midcap product. Not very successful though it made me much more tolerant of those who do sell!

Lazard Capital Markets

2000 - 2003

  • Analyst

    2000 - 2003

    Senior analyst running a team that covered small and midcap European pharmaceutical companies. Extensive marketing of both companies and ideas to fund managers globally.